z-logo
Premium
K v1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model
Author(s) -
Ueyama A.,
Imura K.,
KasaiYamamoto E.,
Tai N.,
Nagira M.,
Shichijo M.,
Yasui K.
Publication year - 2013
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12097
Subject(s) - effector , allergic contact dermatitis , contact dermatitis , medicine , immunology , allergy
Summary Background The K v1.3 voltage‐gated potassium channel is selectively upregulated upon activation in effector memory T ( T EM ) cells in inflamed tissue, and plays an important role in maintenance of T ‐cell activation. Although K v1.3 blockers have been shown to ameliorate allergic contact dermatitis ( ACD ) in a rat model, it remains unknown whether the effect of K v1.3 blockers on ACD is mediated by suppressing T EM cell function and/or whether naive T ‐cells or central memory T ( T CM ) cells are influenced. Aim To analyse the detailed mechanism of K v1.3 blockers in a rat model of ACD . Methods We examined the effects of a K v1.3 blocker on inflammation and production of the effector cytokine interferon ( IFN )‐γ in inflamed tissue in rat ACD . Single‐cell suspensions were isolated from inflamed rat ears ( T EM cells), and regional lymph nodes (naive T / T CM cells), and the effect of K v1.3 blockers on anti‐ CD 3‐stimulated IFN ‐γ production in vitro was measured. Results The K v1.3 blocker significantly suppressed ear inflammation and IFN ‐γ production at the protein level in vivo . It also suppressed in vitro IFN ‐γ production from T EM cells from inflamed tissues, but did not suppress the function of naive T / T CM cells from lymph nodes. Conclusions We found that the K v1.3 blocker ameliorated ACD by inhibiting T EM cell functions only, thus K v1.3 blockers could be a potentially selective therapeutic agent for T EM cell‐mediated inflammatory skin diseases without producing harmful side‐effects.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom